TAKECAB® Now Available for the Treatment of Acid-related Diseases …
2015年2月26日 · TAKECAB, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H +,K +-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal ...
医療用医薬品 : タケキャブ (タケキャブ錠10mg 他) - KEGG
2024年9月18日 · 効能または効果. 胃潰瘍 、 十二指腸潰瘍 、 逆流性食道炎 、低用量アスピリン投与時における 胃潰瘍又は十二指腸潰瘍 の再発抑制、非ステロイド性抗炎症薬投与時における 胃潰瘍又は十二指腸潰瘍 の再発抑制. 下記における ヘリコバクター・ピロリの除菌の補助. 胃潰瘍 、 十二指腸潰瘍 、胃MALTリンパ腫、特発性血小板減少性紫斑病、早期胃癌に対する内視鏡的治療後胃、 ヘリコバクター・ピロリ感染胃炎. 5. 効能または効果に関連する注意. ＜低用 …
Takecab富马酸沃诺拉赞片10mg：50片｜日 药 日本 药局 薬 日本 …
カリウムイオンに競合的な様式でプロトンポンプを阻害することによって、胃酸の生成を抑制します。. 通常、胃・十二指腸潰瘍、逆流性食道炎の治療、低用量アスピリン・非ステロイド性抗炎症薬服用時における胃・十二指腸潰瘍の再発抑制に用いられ ...
Vonoprazan: First Global Approval | Drugs - Springer
2015年3月6日 · Vonoprazan (Takecab ®) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro ...
New Drug Application for Oral Disintegrated Tablet Formulation …
2021年3月22日 · TAKECAB OD tablets are suitable for patients with impaired swallowing, including elderly patients, and the increase in treatment options can also be expected to improve medication adherence. Based on a domestic co-promotion agreement concluded in 2014, Takeda will manufacture and sell TAKECAB OD tablets, with informational activities conducted ...
Takecab Tablets 20mg [agents for killing Helicobacter
2020年1月10日 · It is usually used concomitantly with two antibacterial agents in the treatment of Helicobacter pylori infection in gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura or after endoscopic therapy for …
Takecab Tablets 10mg [agents for killing Helicobacter pylori]
In general, for adults, take 2 tablets (20 mg of vonoprazan) at a time, twice a day for 7 days. Take this medicine together with two antibacterial medicines. Strictly follow the instructions. If you miss a dose, take the missed dose as soon as possible.
VONOSAP® pack 400, VONOSAP® pack 800 and VONOPION® …
2016年6月7日 · VONOSAP is a triple-drug blister pack combining the acid suppressant ((also called a potassium-competitive acid blocker (P-CAB) based on its mechanisms of action)) TAKECAB ® tablet (generic name, vonoprazan fumarate; hereafter “TAKECAB”) developed by Takeda, “Amolin ® capsule” (generic name, amoxicillin; hereafter “Amolin”) and ...
Vonoprazan: First Global Approval | springermedicine.com
Vonoprazan (Takecab ®) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro ...
The First-in-Class Potassium-Competitive Acid Blocker, …
Vonoprazan fumarate (Takecab®) is a first-in-class potassium-competitive acid blocker that has been available in the market in Japan since February …
- 某些结果已被删除